SCHEMBL3092840

SCHEMBL3092840

CC(C)N(C(=O)C(CC1CC1)C(=O)NS(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.44
ERBB2 P04626 3/20 0.44
FLT1 P17948 3/20 0.39
FLT4 P35916 3/20 0.39
KDR P35968 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LTC4S Q16873 2/20 0.38
LMNA P02545 4/20 0.38
USP30 Q70CQ3 1/20 0.38
ELANE P08246 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 2/20 0.36
S1PR1 P21453 1/20 0.36
CYP3A4 P08684 1/20 0.36
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
HTR2A P28223 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097806 0.91 FBP1 (0.36) EGFRERBB2FLT1FLT4KDR
SCHEMBL3087959 0.91 EGFR (0.45) EGFRERBB2MEN1KMT2ALMNA
SCHEMBL3091920 0.90 CCR5 (0.39) FLT1FLT4KDRUSP30
SCHEMBL3083883 0.89 EGFR (0.48) EGFRERBB2MEN1KMT2ALTC4S
SCHEMBL3089589 0.89 USP30 (0.42) USP30ALDH1A1
SCHEMBL3096770 0.89 EGFR (0.39) EGFRERBB2MEN1KMT2ALMNA
SCHEMBL3097794 0.89 BCL2L1 (0.41) MEN1KMT2AUSP30MMP1MMP2
SCHEMBL3092116 0.87 TARS1 (0.48) LMNAMMP1MMP2MMP3MMP8
SCHEMBL3092907 0.87 USP30 (0.41) EGFRERBB2LTC4SUSP30PTGIR
SCHEMBL3092864 0.86 LARS1 (0.48) MEN1KMT2ALMNAHTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 EGFR 346/4885ERBB2 781/4885FLT1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.